Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2009 1
2012 1
2014 1
2015 2
2016 2
2019 1
2021 2
2022 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR, Mishkin DS, Arrisi P, Scalori A, Oh YS, Tole S, Chai A, Chamberlain-James K, Lacey S, McBride J, Panés J; HIBISCUS Study Group. Rubin DT, et al. Among authors: scalori a. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):17-27. doi: 10.1016/S2468-1253(21)00338-1. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798036 Clinical Trial.
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group. Peyrin-Biroulet L, et al. Among authors: scalori a. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798039 Free article. Clinical Trial.
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alonso G, Adkins D, Godbert Y, Ahn MJ, Cassier PA, Cho BC, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzmann S, Brose MS. Subbiah V, et al. Among authors: scalori a. Thyroid. 2024 Jan;34(1):26-40. doi: 10.1089/thy.2023.0363. Thyroid. 2024. PMID: 38009200
Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial.
Zhang W, Scalori A, Fuh F, McBride J, She G, Kierkus J, Korczowksi B, Li R, Abouhossein M, Kadva A, Park KT, Tang MT. Zhang W, et al. Among authors: scalori a. Inflamm Bowel Dis. 2022 Sep 1;28(9):1348-1356. doi: 10.1093/ibd/izab275. Inflamm Bowel Dis. 2022. PMID: 34849918 Free PMC article. Clinical Trial.
Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial.
Zhang W, Scalori A, Fuh F, McBride J, She G, Kierkus J, Korczowski B, Li R, Abouhossein M, Kadva A, Park KT, Tang MT. Zhang W, et al. Among authors: scalori a. Inflamm Bowel Dis. 2022 Oct 3;28(10):e143. doi: 10.1093/ibd/izac066. Inflamm Bowel Dis. 2022. PMID: 35366308 Free PMC article. No abstract available.
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.
Gane EJ, Rouzier R, Hassanein T, Stedman CA, Mazur W, Kupcova V, Le Pogam S, Eng S, Voulgari A, Morcos PN, Brennan BJ, Scalori A, Thommes J. Gane EJ, et al. Among authors: scalori a. Hepatol Int. 2016 May;10(3):478-87. doi: 10.1007/s12072-015-9699-9. Epub 2016 Feb 17. Hepatol Int. 2016. PMID: 26886127 Clinical Trial.
15 results